Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
09/14/2021 - 09:00 AM
MADISON, Wis. --(BUSINESS WIRE)--
Nimble Therapeutics, a biotechnology company revolutionizing the discovery and development of peptide therapeutics, today announced their strategic research collaboration with Incyte (NASDAQ: INCY) has been expanded to include discovery of additional novel peptide therapies.
“Nimble looks forward to building upon on the already strong collaboration between the Nimble and Incyte scientific teams. The expansion of the collaboration serves as yet another important validation of Nimble’s powerful capabilities and approach towards engineering the next generation of peptide therapeutics,” said Jigar Patel , CEO and Founder of Nimble Therapeutics.
Under the terms of the agreement, Nimble will receive an upfront payment and reimbursement of certain research program costs and may become eligible for downstream milestone payments and royalties. Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration and has an option to further expand the collaboration to include additional targets.
About Nimble Therapeutics
Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful analytics to efficiently and intelligently discover and develop next generation peptide therapeutics.
Connect with us on LinkedIn at www.linkedin.com/company/nimble-therapeutics or visit our website at www.nimbletherapeutics.com to learn more.
View source version on businesswire.com : https://www.businesswire.com/news/home/20210914005143/en/
Nimble Therapeutics, Inc.
Brad Garcia , Ph.D.
info@nimbletherapeutics.com
Source: Nimble Therapeutics
INCY Rankings
#3820 Ranked by Stock Gains
INCY Stock Data
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
Wilmington
About INCY
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
